Aspergillus species have emerged as an important cause of life-threatening infections in
immunocompromised patients. This expanding population is composed of patients with …

… David W. Denning conceived the manuscript and assisted with manuscript preparation, data
collection and editing. Felix Bongomin and Sara Gago performed the bibliography review, …

It is important to realize that guidelines cannot always account for individual variation among
patients. They are not intended to supplant physician judgment with respect to particular …

The European Society for Clinical Microbiology and Infectious Diseases, the European
Confederation of Medical Mycology and the European Respiratory Society Joint Clinical …

Since the first description of invasive aspergillosis as an opportunistic infection in 1953 [1],
there has been a substantial increase in the number of cases documented at autopsy in all …

Background and Methods. Symptomatic pulmonary aspergillosis has rarely been reported
in patients with the acquired immunodeficiency syndrome (AIDS). We describe the …

Background Voriconazole is a broad-spectrum triazole that is active against aspergillus
species. We conducted a randomized trial to compare voriconazole with amphotericin B for …

A review of series of ⩾4 cases of invasive aspergillosis (total, 1,223 cases) was undertaken
to establish the crude mortality and rate of response to therapy with amphotericin B in the …

The echinocandins are large lipopeptide molecules that are inhibitors of β-(1,3)-glucan
synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins are …

To evaluate the efficacy and safety of voriconazole in acute invasive aspergillosis (IA), an
open, noncomparative multicenter study was conducted. Immunocompromised patients with IA …